Collegium Pharmaceutical
COLL
279 hedge funds and large institutions have $1.42B invested in Collegium Pharmaceutical in 2026 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 119 increasing their positions, 85 reducing their positions, and 29 closing their positions.
55% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 29
40% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 85
13% more capital invested
Capital invested by funds: $1.26B → $1.42B (+$161M)
4% more funds holding
Funds holding: 267 → 279 (+12)
1.09% more ownership
Funds ownership: 119.61% → 120.7% (+1.1%)
62% less call options, than puts
Call options by funds: $901K | Put options by funds: $2.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Goldentree Asset Management
New York
|
+$25.5M |
| 2 |
Millennium Management
New York
|
+$12.9M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$11.5M |
| 4 |
BlackRock
New York
|
+$10.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$9.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$16.9M |
| 2 |
Two Sigma Investments
New York
|
-$16.5M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$13.7M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$10.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$6.57M |
COLL Hedge Fund Activity: Q2 2026 in Review
279 institutional investors reported a position in Collegium Pharmaceutical (COLL) for Q2 2026, worth a combined $1.42B — up 13% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new COLL positions and 29 closed out — a net gain of 16 holders — while 119 added to existing stakes and 85 trimmed.
The largest buyer was Goldentree Asset Management, opening a new position worth an estimated $25.5M. The largest seller was Marshall Wace, cutting an estimated $16.9M.
- 279 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2026, up from 267 in Q1 2026.
- Funds reported $1.42B of Collegium Pharmaceutical stock for Q2 2026, up 13% quarter-over-quarter.
- 45 funds opened new Collegium Pharmaceutical positions in Q2 2026 and 29 closed out, a net change of +16 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2026 was Goldentree Asset Management, an estimated $25.5M added.
- The largest Collegium Pharmaceutical seller in Q2 2026 was Marshall Wace, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2026.